Trial Profile
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 23 Feb 2023
Price :
$35
*
At a glance
- Drugs Epacadostat (Primary) ; Parsaclisib (Primary) ; Retifanlimab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Incyte Corporation
- 17 Feb 2023 Status changed from active, no longer recruiting to completed.
- 10 Nov 2021 Planned primary completion date changed from 21 Oct 2021 to 22 Jan 2023.
- 27 Aug 2021 Planned End Date changed from 31 Mar 2022 to 22 Jan 2023.